prazosin has been researched along with Nerve Degeneration in 3 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
Excerpt | Relevance | Reference |
---|---|---|
"A novel model of hypertension recently developed in our laboratory shows that neonatal degeneration of capsaicin-sensitive sensory nerves renders a rat responsive to a salt load with a significant rise in blood pressure." | 3.70 | Antihypertensive mechanisms underlying a novel salt-sensitive hypertensive model induced by sensory denervation. ( Li, J; Wang, DH, 1999) |
"We found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses in individuals taking TZ and related drugs." | 1.51 | Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. ( Cai, R; Chen, Z; Consiglio, A; Fernandez-Carasa, I; Gao, L; Han, Y; Ji, X; Li, Y; Liu, L; Narayanan, NS; Polgreen, PM; Raya, A; Schultz, JL; Simmering, JE; Su, W; Welsh, MJ; Yuan, Y; Zhang, Y; Zhao, C, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cai, R | 1 |
Zhang, Y | 1 |
Simmering, JE | 1 |
Schultz, JL | 1 |
Li, Y | 1 |
Fernandez-Carasa, I | 1 |
Consiglio, A | 1 |
Raya, A | 1 |
Polgreen, PM | 1 |
Narayanan, NS | 1 |
Yuan, Y | 1 |
Chen, Z | 1 |
Su, W | 1 |
Han, Y | 1 |
Zhao, C | 1 |
Gao, L | 1 |
Ji, X | 1 |
Welsh, MJ | 1 |
Liu, L | 1 |
Muñoz, A | 1 |
Lopez-Real, A | 1 |
Labandeira-Garcia, JL | 1 |
Guerra, MJ | 1 |
Wang, DH | 1 |
Li, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies[NCT04760860] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2024-10-31 | Not yet recruiting | ||
The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
Assessing Target Engagement of Terazosin in Healthy Adults[NCT04551040] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-03-26 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
3 other studies available for prazosin and Nerve Degeneration
Article | Year |
---|---|
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Interaction between the noradrenergic and serotonergic systems in locomotor hyperactivity and striatal expression of Fos induced by amphetamine in rats.
Topics: Adrenergic alpha-Antagonists; Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimula | 2003 |
Antihypertensive mechanisms underlying a novel salt-sensitive hypertensive model induced by sensory denervation.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Blood Pressure; Body Weight; Calcitonin Gene-Rel | 1999 |